MAGGI, FABRIZIO
 Distribuzione geografica
Continente #
NA - Nord America 12.315
AS - Asia 5.538
EU - Europa 5.009
SA - Sud America 2.108
AF - Africa 128
Continente sconosciuto - Info sul continente non disponibili 11
OC - Oceania 8
Totale 25.117
Nazione #
US - Stati Uniti d'America 12.166
SG - Singapore 2.182
BR - Brasile 1.727
IT - Italia 1.567
VN - Vietnam 1.448
HK - Hong Kong 1.067
IE - Irlanda 872
SE - Svezia 584
DE - Germania 549
RU - Federazione Russa 388
UA - Ucraina 368
CN - Cina 341
GB - Regno Unito 283
AR - Argentina 172
ID - Indonesia 95
FI - Finlandia 89
IN - India 86
JP - Giappone 80
FR - Francia 78
EC - Ecuador 63
CA - Canada 61
BD - Bangladesh 60
MX - Messico 58
ZA - Sudafrica 46
NL - Olanda 40
IQ - Iraq 38
PY - Paraguay 36
PL - Polonia 35
CO - Colombia 34
ES - Italia 31
AT - Austria 29
CL - Cile 24
MA - Marocco 23
BE - Belgio 21
UZ - Uzbekistan 21
PE - Perù 19
TR - Turchia 18
EG - Egitto 17
LT - Lituania 17
VE - Venezuela 17
UY - Uruguay 13
CZ - Repubblica Ceca 12
KE - Kenya 11
PK - Pakistan 11
TN - Tunisia 11
AZ - Azerbaigian 9
DO - Repubblica Dominicana 9
NP - Nepal 9
BG - Bulgaria 8
IL - Israele 8
LB - Libano 8
AE - Emirati Arabi Uniti 7
AU - Australia 7
DZ - Algeria 7
EU - Europa 7
KZ - Kazakistan 7
JO - Giordania 6
OM - Oman 5
AL - Albania 4
HR - Croazia 4
NI - Nicaragua 4
RO - Romania 4
SA - Arabia Saudita 4
SK - Slovacchia (Repubblica Slovacca) 4
BN - Brunei Darussalam 3
BY - Bielorussia 3
EE - Estonia 3
ET - Etiopia 3
GT - Guatemala 3
HN - Honduras 3
HU - Ungheria 3
LK - Sri Lanka 3
PH - Filippine 3
PT - Portogallo 3
XK - ???statistics.table.value.countryCode.XK??? 3
AM - Armenia 2
BH - Bahrain 2
BO - Bolivia 2
BW - Botswana 2
CI - Costa d'Avorio 2
CR - Costa Rica 2
DM - Dominica 2
GA - Gabon 2
GE - Georgia 2
IR - Iran 2
JM - Giamaica 2
MD - Moldavia 2
PR - Porto Rico 2
QA - Qatar 2
SY - Repubblica araba siriana 2
TH - Thailandia 2
TZ - Tanzania 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BT - Bhutan 1
CH - Svizzera 1
CM - Camerun 1
CY - Cipro 1
DJ - Gibuti 1
Totale 25.104
Città #
Fairfield 1.272
Ashburn 1.222
Singapore 1.135
Hong Kong 1.065
Jacksonville 958
Milan 879
Dublin 857
Princeton 735
Dallas 687
Chandler 651
Wilmington 630
Woodbridge 483
Houston 439
Nyköping 438
Seattle 416
Boardman 408
Cambridge 377
Dong Ket 332
Ho Chi Minh City 292
Chicago 280
Los Angeles 234
Beijing 192
Redwood City 175
San Diego 174
The Dalles 168
New York 163
São Paulo 151
Ogden 141
Ann Arbor 137
Hanoi 135
Washington 126
Salt Lake City 109
London 103
Rome 99
Tokyo 75
Santa Clara 74
Como 69
Tampa 66
Elk Grove Village 58
Munich 57
Buffalo 54
Rio de Janeiro 52
Helsinki 49
Haiphong 47
Lancaster 47
Norwalk 45
Brasília 40
Varese 38
Frankfurt am Main 33
Warsaw 32
Belo Horizonte 31
Council Bluffs 31
Da Nang 28
Brooklyn 27
Porto Alegre 27
Denver 25
Sterling 25
Biên Hòa 24
Curitiba 23
Mexico City 23
Nuremberg 23
Orem 23
Stockholm 23
Guarulhos 22
Montreal 22
Campinas 21
Johannesburg 21
Poplar 21
San Francisco 21
Atlanta 20
Turku 20
Brussels 19
Falkenstein 19
Ninh Bình 19
Quito 19
Thái Bình 19
Buenos Aires 18
Kilburn 18
Phoenix 18
Ribeirão Preto 18
Salvador 18
Toronto 18
Dhaka 17
Tashkent 17
Amsterdam 16
Boston 16
Chennai 16
Moscow 16
Asunción 15
Jakarta 15
Lima 15
Sorocaba 15
Goiânia 14
Guayaquil 14
Hải Dương 14
Baghdad 13
Detroit 13
Dulles 13
Miami 13
Bauru 12
Totale 17.467
Nome #
Characterization of a lineage C.36 SARS-CoV-2 isolate with reduced susceptibility to neutralization circulating in Lombardy, Italy 433
Torque Teno Virus: A Promising Biomarker in Kidney Transplant Recipients 246
Previous humoral immunity to the endemic seasonal alphacoronaviruses NL63 and 229E is associated with worse clinical outcome in COVID-19 and suggests original antigenic sin 216
Introduction of SARS-CoV-2 variant of concern 20h/501Y.V2 (B.1.351) from Malawi to Italy 211
Viral hepatitis 199
Torque Teno virus: any pathological role in liver transplanted patients? 183
A Lentiviral Vector-Based, Herpes Simplex Virus 1 (HSV-1) Glycoprotein B Vaccine Affords Cross-Protection against HSV-1 and HSV-2 Genital Infections 179
Torquetenovirus detection in exosomes enriched vesicles circulating in human plasma samples 171
Torquetenovirus DNA drives proinflammatory cytokines production and secretion by immune cells via toll-like receptor 9 162
Tyrosine kinase inhibitors play an antiviral action in patients affected by chronic myeloid leukemia: a possible model supporting their use in the fight against SARS-CoV-2 157
Immunogenicity of anti-SARS-CoV-2 Comirnaty vaccine in patients with lymphomas and myeloma who underwent autologous stem cell transplantation 153
Comparative evaluation of five rapid methods for identifying subtype 1b and 2c hepatitis C virus isolates 147
Multicenter Cross-sectional Study on the Epidemiology of Human Metapneumovirus in Italy, 2022–2024, With a Focus on Adults Over 50 Years of Age 144
An episode of oral mucositis after the first administration of the ChAdOx1 COVID-19 vaccine 142
Circulating SARS-CoV-2 variants in Italy, October 2020-March 2021 138
Immunobiology of the Torque teno viruses and other anelloviruses 136
Impact of Microbial Metabolites on Microbiota–Gut–Brain Ax-is in Inflammatory Bowel Disease 131
5-HT2a inhibitors for progressive multifocal leukoencephalopathy: old drugs for an old disease 128
Anti-SARS-CoV-2 antibody levels and kinetics of vaccine response: potential role for unresolved inflammation following recovery from SARS-CoV-2 infection 127
Mucosal immune response in BNT162b2 COVID-19 vaccine recipients 127
Emergence of SARS-COV-2 Spike Protein Escape Mutation Q493R after Treatment for COVID-19 126
An Italian Multicenter Study on the Epidemiology of Respiratory Syncytial Virus During SARS-CoV-2 Pandemic in Hospitalized Children 125
Zinc Oral Supplementation Induces a Significant Rise of TRECs and T CD4+NaiVe and Prevents the Increase of Ttv Viral Load after Stem Cell Transplantation: The Zenith Study 121
Enhanced in vitro virus expression using 3-dimensional cell culture spheroids for infection 119
SARS-CoV-2 detection in primary thyroid sarcoma: coincidence or interaction? 116
Anti-SARS-CoV-2 RBD IgG responses in convalescent versus naïve BNT162b2 vaccine recipients 115
How Current Direct-Acting Antiviral and Novel Cell Culture Systems for HCV are Shaping Therapy and Molecular Diagnosis of Chronic HCV Infection 114
Breakthrough Infections of E484K-Harboring SARS-CoV-2 Delta Variant, Lombardy, Italy 113
TTV GUIDE IT - A randomised controlled trial to compare the safety, tolerability and preliminary efficacy between standard and torque teno virus-guided immunosuppression in stable adult kidney transplant recipients with low immunological risk in the first year after transplantation - a trial protocol 111
Can interferon-ribavirin effectively treat patients who did not respond to a first conventional therapy by interferon? 109
Introduction of SARS-COV-2 C.37 (WHO VOI lambda) from Peru to Italy 109
HIV-1 NAT minipool during the pre-seroconversion window period: Detection of a repeat blood donor 108
High prevalence of TT virus (TTV) and TTV-like minivirus in cervical swabs 107
Immunogenicity and clinical efficacy of anti-SARS-CoV-2 vaccination in patients with hematological malignancies: results of a prospective cohort study of 365 patients 104
La vaccinazione con la glicoproteina B del virus Herpes Simplex tipo 1 protegge contro l’herpes genitale 103
Absence of xenotropic murine leukemia virus-related virus in italian patients affected by chronic fatigue syndrome, fibromyalgia, or rheumatoid arthritis 103
Anelloviruses and immune competence 100
Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021 98
TT virus in the nasal secretions of children with acute respiratory diseases: Relations to viremia and disease severity 97
Imported SARS-COV-2 Variant P.1 Detected in Traveler Returning from Brazil to Italy 97
Influence of hepatitis C virus (HCV) genotype, HCV RNA load, and alanine aminotransferase level on reduction of HCV RNA after a single administration of interferon alpha 96
Zika Virus: Implications for Public Health 96
5-HT2a inhibitors for progressive multifocal leukoencephalopathy: Old drugs for an old disease 95
Symptomatic SARS-CoV-2 infections after full schedule BNT162b2 vaccination in seropositive healthcare workers: a case series from a single institution 95
Impact of SARS-CoV-2 Omicron and Delta variants in patients requiring intensive care unit (ICU) admission for COVID-19, Northern Italy, December 2021 to January 2022 93
TTV and other anelloviruses: The astonishingly wide spread of a viral infection 91
Sialic acid moieties and 5-HT(2a): Two faces of the same receptor for JC virus? 90
Expansion of L452R-Positive SARS-CoV-2 Omicron Variant, Northern Lombardy, Italy 90
Anellovirus 89
Assessment of prevalence and load of torquetenovirus viremia in a large cohort of healthy blood donors 89
A novel rolling circle amplification assay to detect members of the family Anelloviridae in pigs and humans 89
Asymptomatic SARS-CoV-2 vaccine breakthrough infections in health care workers identified through routine universal surveillance testing 89
Genomic surveillance of SARS-CoV-2 positive passengers on flights from China to Italy, December 2022 88
Torquetenovirus (TTV) load is associated with mortality in Italian elderly subjects 88
Human anelloviruses and the central nervous system 88
SARS-CoV-2 B.1.1.7 reinfection after previous COVID-19 in two immunocompetent Italian patients 88
Mucosal immune response after the booster dose of the BNT162b2 COVID-19 vaccine 86
Anellovirus 86
Torquetenovirus infection and ciliary dysmotility in children with recurrent pneumonia 86
A multidisciplinary approach to study a couple of monozygotic twins discordant for the chronic fatigue syndrome: a focus on potential salivary biomarkers 86
TT virus loads and lymphocyte subpopulations in children with acute respiratory diseases 86
Hyaluronan: A neuroimmune modulator in the microbiota-gut axis 86
Anellovirus 85
Comparative evaluation of molecular methods for the quantitative measure of torquetenovirus (TTV) viremia, the new surrogate marker of immune competence 85
Human metapneumovirus associated with respiratory tract infections in a 3-year study of nasal swabs from infants in Italy 85
Analysis of immune escape variants from antibody‐based therapeutics against covid‐19: A systematic review 85
Assessment of automated high-throughput serological assays for prediction of high-titer SARS-CoV-2 neutralizing antibody 84
Humoral and cell-mediated response against SARS-CoV-2 variants elicited by mRNA vaccine BNT162b2 in healthcare workers: a longitudinal observational study 84
Immunosuppressive monoclonal antibodies: current and next generation 83
Getting the most from the Ebola vaccine success 82
Attempt to classify the clinical impact of DNA viruses according to the ability to activate the innate immune system 82
In vitro sensitivity of human metapneumovirus to type i interferons 82
Molecular properties, biology, and clinical implications of TT virus, a recently identified widespread infectious agent of humans 82
5-HT2a antagonists as a new treatment for JCV-associated progressive multifocal leukoencephalopathy 81
JC virus DNA in healthy brain tissue: a challenge for progressive multifocal leukoencephalopathy diagnosis 81
Cell therapies for treatment of human immunodeficiency virus infection 81
Role of Low-Molecular-Weight Heparin in Hospitalized Patients with Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia: A Prospective Observational Study 81
Detection of Torquetenovirus and Redondovirus DNA in Saliva Samples from SARS-CoV-2-Positive and -Negative Subjects 80
Anellovirus e virus simili 80
During readaptation in vivo, a tissue culture-adapted strain of feline immunodeficiency virus reverts to broad neutralization resistance at different times in individual hosts but through changes at the same position of the surface glycoprotein 80
Immune complexed (IC) hepatitis C virus (HCV) in chronically and acutely HCV-infected patients 80
Patient-blood management for COVID19 convalescent plasma therapy: relevance of affinity and donor–recipient differences in concentration of neutralizing antibodies 80
Torque teno virus (TTV) in multiple sclerosis patients with different patterns of disease 79
The Virome and its Major Component, Anellovirus, a Convoluted System Molding Human Immune Defenses and Possibly Affecting the Development of Asthma and Respiratory Diseases in Childhood 78
Anellovirus 77
Anellovirus 77
Dynamics of persistent TT virus infection, as estimated in patients treated with alpha interferon for concomitant hepatitis C 77
Classification of hepatitis C virus type 2 isolates by phylogenetic analysis of core and NS5 regions 77
Role of Hematopoietic Cells in the Maintenance of Chronic Human Torquetenovirus Plasma Viremia 77
Anellovirus 76
Dynamics of Torque Teno virus plasma DNAemia in allogeneic stem cell transplant recipients 76
Kinetics of anti-SARS-COV2 spike protein IgG and IgA antibodies at 4°C: Implications for convalescent plasma stability 76
Combination therapy with interferon alpha and ribavirin in interferon alpha relapsers 75
TT virus infection of periodontal tissues: A controlled clinical and laboratory pilot study 75
Nasal nitric oxide and nitric oxide synthase expression in primary ciliary dyskinesia 75
Relationships between total plasma load of torquetenovirus (TTV) and TTV genogroups carried 75
Low prevalence of TT virus in the cerebrospinal fluid of viremic patients with central nervous system disorders 75
Xenotropic murine leukaemia virus-related virus is not found in peripheral blood cells from treatment-naive human immunodeficiency virus-positive patients 75
Lymphotropic polyomavirus and progressive multifocal leukoencephalopathy 75
Olfactory and gustatory impairments in COVID-19 patients: role in early diagnosis and interferences by concomitant drugs 75
Totale 10.708
Categoria #
all - tutte 159.940
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 159.940


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20215.434 0 0 0 0 0 2.027 520 617 707 247 397 919
2021/20222.911 240 385 65 113 52 129 178 231 164 572 297 485
2022/20232.581 441 148 149 151 81 637 30 256 370 195 56 67
2023/20242.845 233 234 256 569 573 483 49 79 215 46 17 91
2024/20255.287 19 39 883 102 64 380 98 166 622 366 811 1.737
2025/20266.675 661 795 1.402 2.874 724 219 0 0 0 0 0 0
Totale 25.733